Literature DB >> 21736887

Enhancing effects of acetazolamide on neuronal activity correlate with enhanced visual processing ability in humans.

Rasmus Aamand1, Joshua Skewes, Arne Møller, Angela Fago, Andreas Roepstorff.   

Abstract

Acetazolamide is a potent inhibitor of the reversible hydration of CO(2) catalyzed by the enzyme carbonic anhydrase and is commonly used to increase cerebral blood flow e.g. in order to estimate cerebrovascular reserve. However it is not known whether acetazolamide may positively affect the excitability of neurons in the brain in vivo or cortical processing abilities. To test these possibilities we intravenously administered a low dose (7 mg/kg) acetazolamide to volunteers who performed a demanding visual signal detection task while undergoing whole brain electroencephalographic examinations. Two groups were tested twice on the same task, while receiving acetazolamide or a saline treatment in between the two sessions. Our data indicate that, while the control group showed a decrease in global gamma (30-49 Hz) power across sessions, with no correlation to performance, the acetazolamide group showed increased global gamma power that strongly related to their performance in the signal detection task. This was accompanied by a decrease in the early part of the event related potential in the control group, a decrease not seen in the acetazolamide group. There were no significant differences in blood pressure, ventilation rate, or heart rate between the two groups. It is possible that the differences between the groups, observed in this study, are related to the enhancing effect of acetazolamide on the nitric oxide generation catalyzed by carbonic anhydrase, or to other actions of acetazolamide, e.g. opening of Ca(2+) activated K(+) channels and inhibition of Ca(2+) channels.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21736887     DOI: 10.1016/j.neuropharm.2011.06.010

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Acetazolamide: A New Treatment for Visual Vertigo.

Authors:  Ilya M Sluch; Michael S Elliott; Justin Dvorak; Kai Ding; Bradley K Farris
Journal:  Neuroophthalmology       Date:  2017-08-02

2.  The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.

Authors:  Silvia Fossati; Patrizia Giannoni; Maria E Solesio; Sarah L Cocklin; Erwin Cabrera; Jorge Ghiso; Agueda Rostagno
Journal:  Neurobiol Dis       Date:  2015-11-12       Impact factor: 5.996

3.  CT perfusion with acetazolamide challenge in C6 gliomas and angiogenesis.

Authors:  Na Lu; Yue Di; Xiao-Yuan Feng; Jin-Wei Qiang; Jia-wen Zhang; Yong-gang Wang; Ying Liu
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

4.  Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures.

Authors:  Eva Ruusuvuori; Antje K Huebner; Ilya Kirilkin; Alexey Y Yukin; Peter Blaesse; Mohamed Helmy; Hyo Jung Kang; Malek El Muayed; J Christopher Hennings; Juha Voipio; Nenad Šestan; Christian A Hübner; Kai Kaila
Journal:  EMBO J       Date:  2013-07-23       Impact factor: 11.598

Review 5.  A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer's Disease.

Authors:  Gustavo Provensi; Fabrizio Carta; Alessio Nocentini; Claudiu T Supuran; Fiorella Casamenti; M Beatrice Passani; Silvia Fossati
Journal:  Int J Mol Sci       Date:  2019-09-24       Impact factor: 5.923

6.  Near-infrared transillumination back scattering sounding--new method to assess brain microcirculation in patients with chronic carotid artery stenosis.

Authors:  Andrzej F Frydrychowski; Pawel J Winklewski; Arkadiusz Szarmach; Grzegorz Halena; Tomasz Bandurski
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.